New York, NY, USA, 18 January 2022:
 Evotec partner Celmatix Inc., a biotechnology company focused on ovarian biology, today announced that a third milestone has been achieved in its five-year, multi-target alliance with Evotec. The milestone was triggered by Evotec and Bayer AG advancing a drug programme, centered around a novel Celmatix-identified drug target, into hit-identification.

Worldwide, hundreds of millions of women are struggling with PCOS, the most common endocrine disorder in premenopausal women. While the underlying cause of PCOS is largely unknown, genomic studies suggest a strong genetic connection.

For further information, please follow this link to the full version of the press release from Celmatix.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Evotec SE published this content on 18 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 18 January 2022 13:14:09 UTC.